Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Oral Zavegepant Formulations
NCT06137703Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zavegepant in migraine (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity, Maximum Observed Concentration and 1 more. Started Aug 2022; status: completed.
02
Drugs
zavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06137703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137703.